Title: “Unmasking Hypersomnolence: Diagnostic Precision and Therapeutic Frontiers in NT1, NT2, and IH.”

Thursday, December 18, 2025 at 9:30am-11:00am ET

Overview:

If you have asked yourself, “With over 20% of the general population experiencing sleepiness  but variable contributing factors how do we identify  the person experienced sleepiness that is due to a hypersomnolence disorder?”

Then Unmasking Hypersomnolence: Diagnostic Precision and Therapeutic Frontiers in NT1, NT2, and IH will provide you the playbook to a winning professional practice.  a review of key clinical features and diagnostic opportunities to better  recognize and differentiate  these conditions,  combined with the improved ability  to  elicit the full spectrum of features of cataplexy that may be present,  consider the  role of ICS D3 TR, DSM-VTR and more to achieving a more timely recognition and intervention for people living with NT1, NT2, and IH. The opportunity to dissect methods to improve diagnostic precision and individualize therapeutic intervention will be the key unifying clinical pearls as well as future research opportunities that will ignite enthusiasm about the rapidly evolving sleep space and focus in hypersomnolence disorders.

Learning Objectives:

  • Clarify the Differential Diagnosis of Excessive Daytime Sleepiness
  • Explore the Spectrum of Cataplexy Presentations
  • Apply ICSD-3-TR Criteria for Central Disorders of Hypersomnolence
  • Review Emerging Technology for NT1, NT2, and IH
  • Introduce Emerging Diagnostic Technologies

Panel:

Anne Marie Morse, DO, FAASM (Chair)
Nancy Foldvary-Schaefer, DO, MS
Nathaniel F. Watson, MD, MSc

The webinar is made possible by the SRS Foundation and supported by Takeda Pharmaceuticals.

Complimentary, Advanced Registration is Required.